- Home
- NRC vs ORIC Comparison
NRC vs ORIC Comparison
Compare NRC & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- ORIC
- Stock Information
- Founded
- NRC 1981
- ORIC 2014
- Country
- NRC United States
- ORIC United States
- Employees
- NRC N/A
- ORIC N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- NRC Health Care
- ORIC Health Care
- Exchange
- NRC Nasdaq
- ORIC Nasdaq
- Market Cap
- NRC 310.8M
- ORIC 362.9M
- IPO Year
- NRC N/A
- ORIC 2020
- Fundamental
- Price
- NRC $16.62
- ORIC $9.35
- Analyst Decision
- NRC
- ORIC Strong Buy
- Analyst Count
- NRC 0
- ORIC 8
- Target Price
- NRC N/A
- ORIC $18.83
- AVG Volume (30 Days)
- NRC 85.0K
- ORIC 2.0M
- Earning Date
- NRC 08-05-2025
- ORIC 08-11-2025
- Dividend Yield
- NRC 2.88%
- ORIC N/A
- EPS Growth
- NRC N/A
- ORIC N/A
- EPS
- NRC 1.02
- ORIC N/A
- Revenue
- NRC $141,298,000.00
- ORIC N/A
- Revenue This Year
- NRC N/A
- ORIC N/A
- Revenue Next Year
- NRC N/A
- ORIC N/A
- P/E Ratio
- NRC $16.50
- ORIC N/A
- Revenue Growth
- NRC N/A
- ORIC N/A
- 52 Week Low
- NRC $9.76
- ORIC $3.90
- 52 Week High
- NRC $27.07
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- NRC 77.13
- ORIC 62.84
- Support Level
- NRC $15.80
- ORIC $8.85
- Resistance Level
- NRC $17.10
- ORIC $9.54
- Average True Range (ATR)
- NRC 0.56
- ORIC 0.74
- MACD
- NRC 0.16
- ORIC -0.07
- Stochastic Oscillator
- NRC 93.32
- ORIC 50.98
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.